Haier Biomedical was ranked the number one Chinese brand globally and in overseas sales for life science lab equipment in 2025 by Euromonitor International. This achievement highlights its strong international growth, with a compound annual growth rate above 20%, and extensive global distribution in 160 countries. The company has expanded its R&D and operational capabilities worldwide, serving major pharmaceutical supply chains and achieving significant revenue growth in key markets. Haier Biomedical plans to continue investing in localization and product range expansion to support biopharma labs' efficiency and sustainability.
Eikon Therapeutics presented updated clinical data at the 2026 ASCO meeting showing encouraging results for its EIK1001 drug in first-line treatment of stage 4 non-small cell lung cancer (NSCLC), with a 63.1% response rate and good tolerability. The ...
Bitcoin's 60-day volatility has dropped significantly, approaching levels similar to gold's, which could make it more attractive to institutional investors seeking stable, alternative assets. This reduction in volatility challenges previous concerns ...
SoftBank Group announced plans to invest up to €75 billion (about $87 billion) to build and expand data centers in France, aiming to add 5 gigawatts of capacity. The first phase targets 3.1 gigawatts in the Hauts-de-France region by 2031, with new ce...
Flare's co-founder announced that XRP holders could soon access decentralized finance (DeFi) platforms and smart contract functionalities through Flare's blockchain connectivity technology. This development would allow XRP to be used in lending, borr...
XDC Network has seen two consecutive days of price gains after bouncing off a key ascending trendline that has held for two weeks. Large holders, or whales, have been accumulating during this period of consolidation, signaling confidence despite mark...
